

## CURRICULUM VITAE

**RAJIV R. RATHOD, M.D., M.B.A.**  
*Fellow, American Academy of Ophthalmology*

Office Address:  
Orange County Retina Medical Group  
1200 North Tustin Avenue, Suite 140  
Santa Ana, California 92705  
714-972-8432

### PROFESSIONAL PRACTICE AFFILIATIONS

---

Orange County Retina Medical Group  
Orange County, California  
Physician/Surgeon  
Since July 2012

#### Locations

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
23521 Paseo de Valencia	Suite 309	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

### EDUCATION AND TRAINING

---

#### Vitreo-Retinal Fellowship

University of Illinois  
Chicago, Illinois; 2010-2012

#### Residency

Chief Resident, Ophthalmology  
Washington University School of Medicine  
St. Louis, Missouri; 2009-2010

#### Ophthalmology

Washington University School of Medicine / Barnes-Jewish Hospital  
St. Louis, Missouri; 2006-2009

#### Internship in Medicine

Santa Clara Valley Medical Center Transitional Internship  
Stanford University School of Medicine  
San Jose, California; 2005-2006

#### Medical School

Medical Doctorate  
Vanderbilt University School of Medicine  
Nashville, Tennessee; 2000-2005

**Graduate**

Master of Business Administration  
Owen Graduate School of Management  
Vanderbilt University  
Nashville, Tennessee; 2003-2005

**Undergraduate**

Bachelor of Science, Biological Sciences  
Stanford University  
Stanford, California; 1995-1999

**BOARD CERTIFICATION**

---

American Board of Ophthalmology, Diplomate 2012  
United States Medical Licensing Examination, Diplomate 2006

**MEDICAL LICENSURE**

---

California, issued 2012  
Illinois, through 7/31/14  
Missouri, through 1/31/11

**HONORS**

---

2011 Fellow of the Year Award, University of Illinois at Chicago  
2010 "Golden Apple" Best Teacher Award, Washington University  
2009 Mat Guirgis Pediatric Ophthalmology & Strabismus Award: Outstanding Resident, Washington University  
2009 Ron Burde Award (dedication to teaching and patient care), Washington University  
2008 CareerPhysician Chief Resident Program Competition Winner  
2005 Beta Gamma Sigma, Vanderbilt Chapter  
2004 Tulane Business Plan Competition, Second Place  
2001 Microbes and Defense Society, Vanderbilt University  
2001 Top Spear Award (top student in physiology course), Vanderbilt University

**PROFESSIONAL ORGANIZATIONS**

---

American Academy of Ophthalmology  
American Medical Association  
Chicago Ophthalmological Society  
Missouri Society of Eye Physicians and Surgeons  
St. Louis Ophthalmological Society

## HOSPITAL/SURGERY CENTER AFFILIATIONS

---

2012 – Present	Anaheim Regional Medical Center, Anaheim, California
2012 – Present	Barranca Surgery Center, Irvine, California
2012 – Present	Children's Hospital of Orange County, Orange, California
2012 – Present	Children's Hospital at Mission, Mission Viejo, California
2012 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
2012 – Present	Pacifica Hills Surgery Center, Laguna Hills, California
2012 – Present	St. Joseph Hospital, Orange, California
2012 – Present	St. Jude Medical Center, Fullerton, California
2012 – Present	Western Medical Center, Santa Ana, California

## CLINICAL RESEARCH

---

Six years of experience, prior to July 2012, in conducting research in ophthalmology-related topics including endophthalmitis, vitreoretinal surgery, retinal detachment repair, and sickle cell retinopathy.

01. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA, 2012-Present  
Sub-Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonpecizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD.*
02. Alimera Sciences, Protocol C-01-11-008, Extension Study, 2012-Present  
Sub-Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME.*
03. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013  
Sub-Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
04. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-Present  
Sub-Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
05. Xoma, Protocol X052130/CL3-78989-005, Phase III, 2012-Present  
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
06. Pfizer, Protocol B1181003-1050, Phase II, 2012-Present  
Sub-Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
07. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-Present  
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*

08. Regeneron Protocol VGFTe-AMD-1124 ((RE-VIEW), Phase IV, 2012-Present  
Sub-Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
09. Merck Protocol MK8931—017 (SCH 900931, P07738), Phase 2/3, Collaborative Study, 2012-Present  
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*

## BIBLIOGRAPHY

---

### ARTICLES

01. **Rathod RR**, Mieler WF. An update on the management of intraocular foreign bodies. *Retinal Physician*; April 2011.

### PUBLISHED ABSTRACTS/POSTER PRESENTATIONS

01. **Rathod RR**, Shen DJ, Wang MX. Relationship between stromal ablation depth and hyperopic shift after 6 mm phototherapeutic keratectomy using VISX Star Excimer Laser. *Investigative Ophthalmology and Visual Science* 2002;43:E-Abstract 159.
02. **Rathod RR**, Wang MX, Cohen I. Effects of posterior corneal refractive power change on LASIK; June 2002. American Society of Cataract and Refractive Surgery
03. **Rathod RR**, Khanifar A, Kammer JA. Incidence of glaucoma after repeat penetrating keratoplasty. *Investigative Ophthalmology and Visual Science* 2005;46: E-Abstract 130.
04. **Rathod RR**, Apte RS, Blinder KJ. Safety and outcomes of 25-gauge transconjunctival vitreoretinal surgery. *Investigative Ophthalmology and Visual Science* 2008;49: E-Abstract 6002.
05. **Rathod RR**, Rao PK. Incidence of intraocular infection in the setting of systemic fungal infection. *Investigative Ophthalmology and Visual Science* 2009;50: E-Abstract 3554.
06. **Rathod RR**, Lim JI. Outcomes of retinal detachment repair with relaxing retinectomies in cases of severe proliferative vitreoretinopathy. *Investigative Ophthalmology and Visual Science* 2011;52: E-Abstract 6170.
07. **Rathod RR**, Lim JI. The utility of relaxing retinectomies in repair of recurrent retinal detachments with severe proliferative vitreoretinopathy. Presented as poster at American Society of Retina Specialists Meeting; August 2011.

### PRESENTATIONS

01. The role of submacular surgery in the treatment of choroidal neovascular membranes in POHS. Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; January 31, 2007
02. Posterior reversible encephalopathy syndrome. Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; February 21, 2007.
03. Functional visual loss. Washington University Department of Ophthalmology and Visual Sciences, Grand Rounds; March 27, 2007.

04. Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis: Phase I/II Data. Anaheim, California; October 3, 2012

#### **COMMUNITY INVOLVEMENT**

---

Mobile Eye Care Clinic for the Homeless, Illumination Foundation, Sadelback Memorial Care Hospital, San Clemente, CA; November 4, 2012

#### **LANGUAGES**

---

Medical Spanish, Gujarati